1. Nicastro TM, Mocello AR, Weke E, Bukusi EA, et al.
   Effect of a climate-smart intervention on agriculture and nutrition of people with HIV: a cluster-randomized trial.
   AIDS 2025.
   


2. Hamilton DT, Hoover KW, Delaney KP.
   Reducing HIV incidence in the southern US through routine opt-out HIV screening.
   AIDS 2025.
   


3. Appleton AA, Lee S, Kuniholm MH, Vasquez E, et al.
   Adverse childhood experiences, sexual orientation-related victimization, and cardiovascular disease risk among men living with and without HIV.
   AIDS 2025.
   


4. Li H, Guo Q, Feng Y, Liao L, et al.
   Identification of Two Novel HIV-1 Unique Recombinant Forms Among Men Who Have Sex with Men in Northern China.
   AIDS Res Hum Retroviruses 2025.
   


5. Sturny-Leclere A, Francoise U, Badje AD, Garcia-Hermoso D, et al.
   Histoplasma antigenuria prevalence in patients with advanced HIV disease in Cote d'Ivoire: a prospective trial ancillary study.
   Clin Infect Dis 2025.
   


6. Han WM, Ryom L, Sabin CA, Greenberg L, et al.
   Risk of cancer in people with HIV experiencing varying degrees of immune recovery with sustained virological suppression on antiretroviral treatment for more than 2 years: an international, multicentre, observational cohort.
   Clin Infect Dis 2025.
   


7. Schwartz IS, Pasqualotto AC.
   Histoplasma antigen screening in advanced HIV disease.
   Clin Infect Dis 2025.
   


8. Konopnicki D, Gilles C, Manigart Y, Barlow P, et al.
   Immunogenicity and safety of two versus three doses of 9-valent vaccine against Human papillomavirus (HPV) in women with HIV: the Papillon randomized trial.
   Clin Infect Dis 2025.
   


9. Hawkins KL, Dandachi D, Verzani Z, Brannock MD, et al.
   HIV Infection and Long COVID: A RECOVER Program, Electronic Health Record Based Cohort Study.
   Clin Infect Dis 2025.
   


10. Stadler JAM, Kuhlin JJ, Molloy SF, Mtwa NN, et al.
    Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa.
    Clin Infect Dis 2025.
    


11. Anderer S.
    One Million New Pediatric HIV Cases Predicted If PEPFAR Funding Is Cut.
    JAMA 2025.
    


12. Onwubiko UN, Benkeser D, Holland DP, Baral SD, et al.
    Impact of Depression at HIV PrEP Initiation on Sustained PrEP Care Engagement Among US Gay and Bisexual Men.
    J Acquir Immune Defic Syndr 2025.
    


13. Huang YA, Patel RR, Mann LM, Zhu W, et al.
    Out-of-pocket costs for PrEP ancillary services among U.S. commercially insured persons, 2017-2022.
    J Acquir Immune Defic Syndr 2025.
    


14. Patten G, Haas AD, Davies MA, Maartens G, et al.
    Association between changes in script renewal periods and HIV viral non-suppression: a cohort study of a South African private-sector HIV program.
    J Acquir Immune Defic Syndr 2025.
    


15. Sudderuddin H, Dang Z, Watson B, Atkinson K, et al.
    Investigation of Integrase Inhibitor Resistance Mutations in gp41 in Clinical Samples.
    J Acquir Immune Defic Syndr 2025.
    


16. Cressey TR, Salvadori N, Rabie H, du Toit S, et al.
    Single Doses of Pediatric Dolutegravir Dispersible Tablets in Neonates Support Multidosing: PETITE-Dolutegravir Study.
    J Acquir Immune Defic Syndr 2025;99:195-201.
    


17. Yu F, Ma P, Duan J.
    Reevaluating the clinical relevance of bacterial vaginosis-associated immune responses in HIV infection.
    J Infect Dis 2025.
    


18. Robinson-Papp J, Mehta M, Mueller BR, Neupane N, et al.
    Gastrointestinal Dysmotility, Autonomic Function and Small Intestinal Bacterial Overgrowth among People with Well-Controlled HIV.
    J Infect Dis 2025.
    


19. Sutar J, Jayal P, Mullick R, Chaudhary S, et al.
    Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies.
    J Virol 2025.
    


20. Greber UF.
    Clicking viruses-with chemistry toward mechanisms in infection.
    J Virol 2025.
    


21. Musiime V, Bwakura-Dangarembizi M, Szubert AJ, Mumbiro V, et al.
    Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
    N Engl J Med 2025;392:1917-1932.
    


22. Roberts ET, Phelan J, Schwartz AL, Meara E, et al.
    Loss of Subsidized Drug Coverage and Mortality among Medicare Beneficiaries.
    N Engl J Med 2025.
    


23. Caniels TG, Prabhakaran M, Ozorowski G, MacPhee KJ, et al.
    Precise targeting of HIV broadly neutralizing antibody precursors in humans.
    Science 2025.
    


24. Willis JR, Prabhakaran M, Muthui M, Naidoo A, et al.
    Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans.
    Science 2025.
    

Display articles in

• Abstract format